Allopurinol

證據等級: L5

預測適應症: 10 個

Allopurinol: From Gout and Hyperuricemia to Hepatic Porphyria

One-Sentence Summary

Allopurinol is a well-established xanthine oxidase (XO) inhibitor widely used to treat gout and hyperuricemia by reducing hepatic uric acid production. The TxGNN model predicts it may be effective for Hepatic Porphyria, with 0 clinical trials and 2 publications currently supporting this direction.

Quick Overview

Item	Content
Original Indication	Gout and hyperuricemia (NPRA product-level details pending retrieval)
Predicted New Indication	Hepatic Porphyria
TxGNN Prediction Score	99.95%
Evidence Level	L4
Malaysia Market Status	✓ Marketed
Number of Registrations	11
Recommended Decision	Hold

Why is This Prediction Reasonable?

Allopurinol inhibits xanthine oxidase (XO), the enzyme responsible for the final two steps of purine catabolism that convert hypoxanthine → xanthine → uric acid. Beyond lowering serum uric acid, XO inhibition also curtails the generation of reactive oxygen species (superoxide radicals), giving allopurinol a meaningful secondary antioxidant effect — particularly in metabolically active tissues such as the liver.

The proposed connection to hepatic porphyria rests on two mechanistic threads. First, hypothesis-level literature proposes that allopurinol may suppress δ-aminolevulinate synthase 1 (ALAS1) — the rate-limiting enzyme in hepatic heme biosynthesis — by indirectly stabilising the small hepatic regulatory heme pool. In acute hepatic porphyria, the core pathology is excessive ALAS1 induction, which floods the metabolic pathway with toxic precursors (ALA and PBG); dampening ALAS1 could theoretically reduce this precursor accumulation during acute attacks. Second, oxidative stress generated by XO-derived superoxide may worsen the hepatic metabolic environment in porphyria, and allopurinol’s antioxidant action could provide indirect mitigation.

It must be emphasised that both threads remain at the hypothesis stage. The two retrieved publications are mechanistic/animal studies that discuss the broader ALAS1 regulatory framework and drug-porphyria interactions — neither directly tests allopurinol as a porphyria treatment. No clinical or dedicated preclinical studies have been conducted, and formal mechanism-of-action data confirming ALAS1 inhibition by allopurinol was not available in this evidence pack.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
31443750	2019	Hypothesis / Mechanistic	Medical Hypotheses	Proposes that metabolic targeting of ALAS1 — via inhibition of heme utilisation by tryptophan 2,3-dioxygenase (TDO) or tryptophan administration — could suppress porphyric attacks; provides the theoretical framework under which ALAS1 inhibitors such as allopurinol might be relevant
1567472	1992	Animal Study (Rat)	Biochemical Pharmacology	Demonstrates that carbamazepine exacerbates hepatic porphyria by depleting the hepatic regulatory heme pool and inducing ALAS1; establishes a validated animal screening model for drug-porphyria interactions that could be used to formally test allopurinol

Malaysia Market Information

NPRA records confirm 11 active product registrations for Allopurinol in Malaysia (market status: ✓ Marketed). However, individual product details — including product names, dosage forms, manufacturers, and approved indication texts — were not available in the current dataset. Please consult the NPRA Drug Registration database directly for complete authorisation records.

Safety Considerations

Please refer to the package insert for safety information.

Critical Pharmacogenomic Note for Malaysian Clinical Context: Allopurinol is a leading cause of severe cutaneous adverse reactions (SCAR), including Stevens-Johnson Syndrome (SJS/TEN) and DRESS syndrome. The HLA-B*58:01 allele, which confers dramatically elevated risk, is present in approximately 6–8% of the Malaysian population (particularly in Han Chinese and some Malay subgroups). Clinical pharmacogenomics guidelines — including those from the Clinical Pharmacogenomics Implementation Consortium (CPIC) — strongly recommend HLA-B*58:01 screening before initiating allopurinol in at-risk Asian populations. This safety consideration would be especially important if any new indication were to expand allopurinol’s use to a broader patient population.

Conclusion and Next Steps

Decision: Hold

Rationale: The mechanistic hypothesis connecting allopurinol to hepatic porphyria via ALAS1 suppression and XO-mediated antioxidant effects is biologically coherent, but the evidence base consists entirely of indirect mechanistic literature — no dedicated preclinical or clinical studies exist to validate the hypothesis, placing this firmly at Evidence Level L4 (mechanistic/preclinical stage) with a research question framing rather than a development pathway.

To proceed, the following is needed:

Preclinical validation: Cell-based assays and animal models (e.g., the rat porphyria screening model from PMID 1567472) directly evaluating allopurinol’s effect on ALAS1 activity, ALA/PBG precursor levels, and hepatic heme pool dynamics
MOA confirmation: Retrieval of DrugBank mechanism-of-action data (DB00437) to formally confirm or refute ALAS1 inhibitory activity as a documented secondary mechanism
Safety package retrieval: Download and parse TFDA/NPRA package insert PDFs to populate key warnings, contraindications, and DDI data — particularly hepatotoxicity signals relevant to a hepatic target disease
NPRA product detail retrieval: Obtain individual registration records (product names, dosage forms, approved indications) to confirm current regulatory scope and route availability
Pharmacogenomic risk framework: Define HLA-B*58:01 screening protocol and risk stratification plan appropriate for the Malaysian patient population before any expanded indication can be considered
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.